Acurx Pharmaceuticals Inc. has announced the publication of scientific research results from its collaboration with Leiden University Medical Center, revealing for the first time the structure of ibezapolstat, a DNA polymerase IIIC (pol IIIC) inhibitor, bound to its bacterial target. The findings, published in Nature Communications, highlight the unique way ibezapolstat selectively targets Gram-positive priority pathogens, including C. difficile, MRSA, VRE, and PRSP. These results build on previously reported Phase 2 clinical efficacy of ibezapolstat in treating C. difficile infection, with a 96% initial cure rate and no recurrence. The new structural insights are already being used to advance the design of next-generation antibiotics against multi-drug-resistant bacteria.